Table 4.

Relationship of disease-free survival to prognostic factors

Prognostic factors	n	Disease-free survival at median time of follow up	Univariate analysis		Multivariate analysis
HR	95% CI	p	HR	95% CI	p
Performance status	0	66	76%			<0.001
	1	73	74%	1.21	0.69–2.14
	2	41	35%	2.73	1.51–4.96
	3	9	38%	3.79	1.41–10.17
Not known	13	77%	0.52	0.19–1.39
Age group (years)	<70	72	80%			<0.001			<0.001
	70–79	63	75%	1.39	0075–2.58		1.39	0.75–2.58
	80–89	57	42%	4.39	2.47–7.80		4.39	2.47–7.80
≥90	8	50%	3.15	1.24–8.00		4.15	1.24–8.00
Tumour stage	cT1	21	70%			0.79
	cT2	89	72%	1.31	0.62–2.80
	cT3	87	59%	1.46	0.67–3.17
cT4	3	67%	0.97	0.12–7.78
Nodal stage	Negative	125	69%			0.99
	Positive	74	62%	1.01	0.63–1.62
Not known	1	–	0.00	0.00
Distant from anal verge	<7 cm	144	68%			0.28
	7–11 cm	47	59%	1.47	0.92–2.33
	>11 cm	2	–	1.43	0.20–10.38
Not known	7	71%	0.53	0.13–2.17
Tumour size	≤3 cm	107	72%			0.44
	>3 cm	65	60%	1.33	0.83–2.13
Not known	28	59%	1.29	0.71–2.36
Treatment modality	RT alone	127	54%			0.002
	Chemoradiation	56	71%	2.27	1.44–3.56
CXB alone	17	71%	1.47	0.69–3.14
Papillion total dose	≤90 Gy	168	66%			0.70
>90 Gy	32	64%	1.11	0.65–1.92

CXB, contact X-ray brachytherapy; RT, radiotherapy.